Literature DB >> 11501573

Leukoreduction of sickle cell trait blood: an unresolved issue.

P Krailadsiri1, R Gilcher, J Seghatchian.   

Abstract

With the increasing demand for leukoreduction of blood components and the implementation of universal leukoreduction in several countries, the problems associated with leukocyte filtration of sickle cell trait blood have been revisited. Currently, there is no unified standard practice for sickle cell trait donors. Different blood centers adopt different policies. While some defer these donors from red cell component donation, some do not. Some screen all ethnic African donors for hemoglobin S (Hb S), others do not. Furthermore, there are differences in views of whether sickle cell trait red cells should be considered as equivalent to non-sickle cell trait red cells. Some blood centers do not give red cells from a sickle cell trait donor to the newborn or patients undergoing general anesthesia as a preventative measure. In this presentation, we discuss the epidemiology of the sickle gene, the sickling process, problems associated with leukoreduction of sickle cell trait whole blood and red cells, and some unresolved issues concerning donor referral and the usage of sickle cell trait blood.

Entities:  

Mesh:

Year:  2001        PMID: 11501573     DOI: 10.1016/s1473-0502(01)00054-4

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  3 in total

1.  Assessment of leucoreduction of sickle cell trait blood: quality of the filtered product.

Authors:  Karim Ould Amar; Olivier Bourdonné; Sylvie Bruneau; Fatiha Sellami; Pascale Richard
Journal:  Blood Transfus       Date:  2012-10-30       Impact factor: 3.443

2.  Sickle cell trait results in a high leukoreduction quality control failure rate for whole blood donations.

Authors:  Eric A Gehrie; Lori Petran; Pampee P Young
Journal:  Transfusion       Date:  2022-07-15       Impact factor: 3.337

3.  Hemoglobin S identification in blood donors: A cross section of prevalence.

Authors:  Fernanda Lima Kroger; Ianka Cristina Ernesto; Marina Schuffner Silva; Olivia Franco Dos Santos; Renato Lourenço de Medeiros; Daniela de Oliveira Werneck Rodrigues
Journal:  Hematol Transfus Cell Ther       Date:  2021-01-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.